Key Takeaways
- • PCI Pharma Services valued at $10 billion in a strategic investment round co-led by Bain Capital and existing lead investor Kohlberg Kravis Roberts, with significant reinvestment from Mubadala Investment Company and continued minority support from Partners Group.
- • Bain Capital enters PCI's cap table for the first time, while Kohlberg and Mubadala, original investors from 2020, double down on the Philadelphia-based CDMO ahead of completed transatlantic expansions and recent acquisition of Ajinomoto Althea.
- • Capital deployment targets geographic and service expansion, including growth of injectable fill-finish capabilities, high-potency manufacturing, and drug-device assembly and packaging operations, following a $365 million prior investment in these areas.
- • CDMO market tailwinds support thesis: The sector is projected to double from $173 billion to $345 billion by 2033, positioning PCI to capitalize on rising demand for contract drug manufacturing among biopharmaceutical companies.
- • Multi-sponsor syndication signals confidence in PCI's competitive positioning and ability to accelerate customer acquisition and deliver innovative biologics to market through enhanced service capabilities.
Summary
PCI Pharma Services, a Philadelphia-based contract development and manufacturing organization (CDMO), has secured a strategic investment valued at $10 billion, according to The Wall Street Journal. The round was co-led by Bain Capital, marking the firm's entry into PCI's investor base, alongside existing lead investor Kohlberg Kravis Roberts. Mubadala Investment Company made a significant reinvestment, while Partners Group will maintain its minority stake, according to PCI's July 14 press release. The company withheld specific financial terms from public disclosure, though a company representative characterized the round as "both sizable and significant."
Kohlberg and Mubadala first invested in PCI in 2020, demonstrating sustained conviction in the company's trajectory. The consortium of private equity sponsors is now partnering with PCI's management team to accelerate growth, strengthen customer service capabilities, and expand the company's ability to deliver innovative biologics to market. This investment arrives at a strategic juncture for PCI, with transatlantic expansions nearing completion and the recently finalized acquisition of Ajinomoto Althea, a leading U.S.-based sterile fill-finish CDMO, already integrated into operations.
PCI plans to deploy the capital toward both internal development and external acquisition opportunities, with explicit focus on expanding its CDMO service offerings and geographic footprint. Priority expansion areas include enhanced injectable fill-finish capabilities, high-potency manufacturing, and specialized manufacturing services. This strategy aligns with a September-initiated $365 million investment program focused on upgrading assembly and packaging capabilities for drug-device combinations across domestic and international locations.
The timing of this investment reflects favorable market fundamentals in the CDMO sector. Industry projections indicate the global CDMO market will expand from $173 billion to $345 billion by 2033—a compound doubling over an eight-year horizon—driven by biopharmaceutical companies' continued outsourcing of manufacturing to specialized providers. The multi-sponsor participation from established private equity firms signals confidence in PCI's competitive positioning and management execution within this expanding market.
Kohlberg and Mubadala first invested in PCI in 2020, demonstrating sustained conviction in the company's trajectory. The consortium of private equity sponsors is now partnering with PCI's management team to accelerate growth, strengthen customer service capabilities, and expand the company's ability to deliver innovative biologics to market. This investment arrives at a strategic juncture for PCI, with transatlantic expansions nearing completion and the recently finalized acquisition of Ajinomoto Althea, a leading U.S.-based sterile fill-finish CDMO, already integrated into operations.
PCI plans to deploy the capital toward both internal development and external acquisition opportunities, with explicit focus on expanding its CDMO service offerings and geographic footprint. Priority expansion areas include enhanced injectable fill-finish capabilities, high-potency manufacturing, and specialized manufacturing services. This strategy aligns with a September-initiated $365 million investment program focused on upgrading assembly and packaging capabilities for drug-device combinations across domestic and international locations.
The timing of this investment reflects favorable market fundamentals in the CDMO sector. Industry projections indicate the global CDMO market will expand from $173 billion to $345 billion by 2033—a compound doubling over an eight-year horizon—driven by biopharmaceutical companies' continued outsourcing of manufacturing to specialized providers. The multi-sponsor participation from established private equity firms signals confidence in PCI's competitive positioning and management execution within this expanding market.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.